The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR
Open accessAbstract
The receptor tyrosine kinase/PI3K/Akt/mammalian target of rapamycin (RTK/PI3K/Akt/mTOR) pathway is frequently altered in tumors. Inactivating mutations of either the TSC1 or the TSC2 tumor-suppressor genes cause tuberous sclerosis complex (TSC), a benign tumor syndrome in which there is both hyperactivation of mTOR and inhibition of RTK/PI3K/Akt signaling, partially due to reduced PDGFR expression. We report here that activation of PI3K or Akt, or deletion of phosphatase and tensin homolog (PTEN) in mouse embryonic fibroblasts (MEFs) also suppresses PDGFR expression. This was a direct effect of mTOR activation, since rapamycin restored PDGFR expression and PDGF-sensitive Akt activation in Tsc1-/- and Tsc2-/- cells. Akt activation in response to EGF in Tsc2-/- cells was also reduced. Furthermore, Akt activation in response to each of EGF, IGF, and PMA was reduced in cells lacking both PDGFRalpha and PDGFRbeta, implying a role for PDGFR in transmission of growth signals downstream of these stimuli. Consistent with the reduction in PI3K/Akt signaling, in a nude mouse model both Tsc1-/- and Tsc2-/- cells had reduced tumorigenic potential in comparison to control cells, which was enhanced by expression of either active Akt or PDGFRbeta. In conclusion, PDGFR is a major target of negative feedback regulation in cells with activated mTOR, which limits the growth potential of TSC tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185
The biology of platelet-derived growth factor
Ross, R., Raines, E. W., & Bowen-Pope, D. F. (1986) · Cell · doi:10.1016/0092-8674(86)90733-6 · Cited by 2,008
Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action
Hara, K., Maruki, Y., Long, X., Yoshino, K.-I., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J., & Yonezawa, K. (2002) · Cell · doi:10.1016/s0092-8674(02)00833-4 · Cited by 1,810
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
Cully, M., You, H., Levine, A. J., & Mak, T. W. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1819 · Cited by 1,233
The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins
Harrington, L. S., Findlay, G. M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R., et al. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200403069 · Cited by 1,123
Ligand-Induced, Receptor-Mediated Dimerization and Activation of EGF Receptor
Schlessinger, J. (2002) · Cell · doi:10.1016/s0092-8674(02)00966-2 · Cited by 993
Akt regulates growth by directly phosphorylating Tsc2
Potter, C. J., Pedraza, L. G., & Xu, T. (2002) · Nature Cell Biology · doi:10.1038/ncb840 · Cited by 959
The Akt-mTOR tango and its relevance to cancer
Hay, N. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.008 · Cited by 821
Shah, O. J., Wang, Z., & Hunter, T. (2004) · Current Biology · doi:10.1016/j.cub.2004.08.026 · Cited by 798
Kwiatkowski, D. J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.5.525 · Cited by 667
Self-citationRapamycin causes regression of astrocytomas in tuberous sclerosis complex
Franz, D. N., Leonard, J., Tudor, C., Chuck, G., Care, M., Sethuraman, G., Dinopoulos, A., Thomas, G., & Crone, K. R. (2006) · Annals of Neurology · doi:10.1002/ana.20784 · Cited by 614
Mutations in a signalling pathway
Parsons, D. W., Wang, T.-L., Samuels, Y., Bardelli, A., Cummins, J. M., DeLong, L., Silliman, N., Ptak, J., Szabo, S., Willson, J. K. V., et al. (2005) · Nature · doi:10.1038/436792a · Cited by 599
Mechanism of Divergent Growth Factor Effects in Mesenchymal Stem Cell Differentiation
Kratchmarova, I., Blagoev, B., Haack-Sorensen, M., Kassem, M., & Mann, M. (2005) · Science · doi:10.1126/science.1107627 · Cited by 565
Corradetti, M. N., Inoki, K., Bardeesy, N., DePinho, R. A., & Guan, K.-L. (2004) · Genes & Development · doi:10.1101/gad.1199104 · Cited by 560
Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR
Zhang, H., Cicchetti, G., Onda, H., Koon, H. B., Asrican, K., Bajraszewski, N., Vazquez, F., Carpenter, C. L., & Kwiatkowski, D. J. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17222 · Cited by 538
Self-citationOncogenic PI3K and its role in cancer
Samuels, Y., & Ericson, K. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000198021.99347.b9 · Cited by 521
TSC2: filling the GAP in the mTOR signaling pathway
Li, Y. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2003.11.007 · Cited by 419
PDGF signaling in cells and mice
Tallquist, M., & Kazlauskas, A. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.03.003 · Cited by 392
Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning
Cai, S.-L., Tee, A. R., Short, J. D., Bergeron, J. M., Kim, J., Shen, J., Guo, R., Johnson, C. L., Kiguchi, K., & Walker, C. L. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200507119 · Cited by 359
Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways
Kwiatkowski, D. J., & Manning, B. D. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi260 · Cited by 332
Self-citationOncogenic protein tyrosine kinases: Kit as a human oncogenic tyrosine kinase
Kitamura, Y., & Hirotab, S. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4273-y · Cited by 260
Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2
Manning, B. D., Logsdon, M. N., Lipovsky, A. I., Abbott, D., Kwiatkowski, D. J., & Cantley, L. C. (2005) · Genes & Development · doi:10.1101/gad.1314605 · Cited by 235
Self-citationHuman cancer, PTEN and the PI-3 kinase pathway
Parsons, R. (2004) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2003.12.021 · Cited by 224
Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease
Astrinidis, A., & Henske, E. P. (2005) · Oncogene · doi:10.1038/sj.onc.1209090 · Cited by 209
Jaeschke, A., Hartkamp, J., Saitoh, M., Roworth, W., Nobukuni, T., Hodges, A., Sampson, J., Thomas, G., & Lamb, R. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.jcb.200206108 · Cited by 206
Saito, Y., Haendeler, J., Hojo, Y., Yamamoto, K., & Berk, B. C. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.19.6387-6394.2001 · Cited by 180
Maxwell, M., Naber, S. P., Wolfe, H. J., Galanopoulos, T., Hedley-Whyte, E. T., Black, P. M., & Antoniades, H. N. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114675 · Cited by 179
Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice
You, M. J., Castrillón, D. H., Bastian, B. C., O’Hagan, R. C., Bosenberg, M., Parsons, R. E., Chin, L., & DePinho, R. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022632099 · Cited by 171
Efficacy of a rapamycin analog (CCI‐779) and IFN‐γ in tuberous sclerosis mouse models
Lee, L., Sudentas, P., Donohue, B., Asrican, K., Worku, A., Walker, V., Sun, Y., Schmidt, K., Albert, M. S., El‐Hashemite, N., et al. (2005) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20118 · Cited by 167
Self-citationEffects of Rapamycin in the Eker Rat Model of Tuberous Sclerosis Complex
Kenerson, H., Dundon, T. A., & Yeung, R. S. (2005) · Pediatric Research · doi:10.1203/01.pdr.0000147727.78571.07 · Cited by 162
Epidermal Growth Factor Receptor Mutations in Patients with Non–Small Cell Lung Cancer
Johnson, B. E., & Janne, P. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1257 · Cited by 153
Oncogenic protein tyrosine kinases
Jones, A. V., & Cross, N. C. P. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4272-z · Cited by 134
Platelet-derived growth factor plays a key role in proliferative vitreoretinopathy.
Andrews, A., Balciunaite, E., Leong, F. L., Tallquist, M. D., Soriano, P. M., Refojo, M. F., & Kazlauskas, A. (1999) · PubMed · Cited by 132
PDGFRB is overexpressed in metastatic medulloblastoma
Gilbertson, R. J., & Clifford, S. C. (2003) · Nature Genetics · doi:10.1038/ng1103-197 · Cited by 112
Mechanism for the transcriptional repression by c-Myc on PDGF β-receptor
Izumi, H., Molander, C., Penn, L. Z., Ishisaki, A., Kohno, K., & Funa, K. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.8.1533 · Cited by 103
Han, S., Santos, T. M., Puga, A. C., Roy, J., Thiele, E. A., McCollin, M., Stemmer-Rachamimov, A. O., & Ramesh, V. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3277 · Cited by 83
mTOR and cancer: reason for dancing at the crossroads?
THOMAS, G. V. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2005.12.003 · Cited by 82
Dolloff, N. G., Shulby, S. S., Nelson, A., Stearns, M. E., Johannes, G. J., Thomas, J. D., Meucci, O., & Fatatis, A. (2005) · Oncogene · doi:10.1038/sj.onc.1208815 · Cited by 69
Finlay, G. A., York, B., Karas, R. H., Fanburg, B. L., Zhang, H., Kwiatkowski, D. J., & Noonan, D. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401912200 · Cited by 66
Self-citationChen, N., Ma, W.-Y., She, Q., Wu, E., Liu, G., Bode, A. M., & Dong, Z. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107156200 · Cited by 60
Self-citationEl-Hashemite, N., Zhang, H., Walker, V., Hoffmeister, K. M., & Kwiatkowski, D. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3609 · Cited by 54
Self-citationGovindarajan, B., Mizesko, M. C., Miller, M. S., Onda, H., Nunnelley, M., Casper, K. A., Brat, D. J., Cohen, C., Arbiser, J. L., & Nunnelly, M. (2003) · PubMed · Cited by 34
Hackzell, A., Uramoto, H., Izumi, H., Kohno, K., & Funa, K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204483200 · Cited by 33
Cited by
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Laplante, M., & Sabatini, D. M. (2009) · Journal of Cell Science · doi:10.1242/jcs.051011 · Cited by 2,170
Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381
Metadata
- Authors
- Zhang, H., Bajraszewski, N., Wu, E., Wang, H., Moseman, A. P., Dabora, S. L., Griffin, J. D., & Kwiatkowski, D. J.
- Venue
- Journal of Clinical Investigation
- Published
- 2007-03-01
- Volume
- 117
- Issue
- 3
- Pages
- 730-738
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2160200374
- Cited by
- 381
- References
- 50
- FWCI
- 9.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.